Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.53 |
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071895 | 1.00 | DRD3 (0.53) | DRD3HTR2ADRD2PRKAA2UTS2R | |
| SCHEMBL14715784 | 0.90 | DRD3 (0.60) | DRD3HTR2ADRD2UTS2RPOLB | |
| SCHEMBL3081406 | 0.90 | DRD3 (0.60) | DRD3HTR2ADRD2UTS2RPOLB | |
| SCHEMBL4076666 | 0.88 | DRD2 (0.56) | DRD3HTR2ADRD2 | |
| SCHEMBL4081506 | 0.87 | PRKAA2 (0.60) | DRD3HTR2ADRD2PRKAA2 | |
| SCHEMBL3079469 | 0.87 | PRKAA2 (0.60) | DRD3HTR2ADRD2PRKAA2 | |
| SCHEMBL14715601 | 0.84 | DRD3 (0.55) | DRD3HTR2ADRD2 | |
| SCHEMBL3086334 | 0.84 | DRD3 (0.55) | DRD3HTR2ADRD2 | |
| SCHEMBL3093402 | 0.84 | DRD2 (0.49) | DRD3HTR2ADRD2 | |
| SCHEMBL27882701 | 0.84 | HRH1 (0.47) | DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | claimed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | DRD3 71/4885HTR2A 565/4885DRD2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.